Study Reveals Importance Of Timing For Cellular Signals, Suggests Possible Tactic For Cancer Therapeutics
Magic tricks work because they take advantage of the brain’s sensory assumptions, tricking audiences into seeing phantoms or overlooking sleights of hand. Now a team of UC San Francisco researchers has discovered that even brainless single-celled yeast have sensory biases that can be hacked by a carefully engineered illusion, a finding that could be used to develop new approaches to fighting diseases such as cancer.
“The ability to perceive and respond to the environment is a basic attribute of all living organisms, from the greatest to the smallest,” said Wendell Lim, PhD, the study’s senior author. “And so is the susceptibility to misperception. It doesn’t matter if the illusion is based on molecular sensors within a single cell or neurons in the brain.”
In the new study, published online Nov. 19, 2015 in Science Express, Lim and his team discovered that yeast cells falsely perceive a specifically timed pattern of stress – caused by alternating between low and mildly increased sodium levels – as a massive, continuously increasing ramp of stress. In response, the microbes end up over-responding and killing themselves. The results, Lim says, suggest a whole new way of looking at the perceptual abilities of simple cells and could even be used to develop new approaches to fighting diseases using the power of illusion.
Timing of stress response is yeast cells’ ‘Achilles heel’
“This discovery was a bit of an accident actually,” said Lim, chair of the Department of Cellular and Molecular Pharmacology at UCSF, director of the UCSF Center for Systems and Synthetic Biology, and a Howard Hughes Medical Institute (HHMI) investigator. “We were interested in the general issue of how cells interpret information over time. Frequency is a key aspect of all our communications, whether it’s hearing language or transmitting radio signals, but do cells themselves use this kind of information? It’s something we don’t know much about.”
To explore this question, two postdoctoral fellows in Lim’s lab, Ping Wei, PhD, now at Peking University School of Life Sciences, and Amir Mitchell, PhD, set up a system that allowed them to expose yeast to a mild stressor – a small increase in salt in the yeast’s environment – and to oscillate between the increased salt level and the baseline level at different frequencies.
Normally, sensor molecules in a yeast cell detect changes in salt concentration and instruct the cell to respond by producing a protective chemical. After this transient response, the cell can resume growing happily as if conditions had not changed. The researchers found that the cells were perfectly capable of adapting when they flipped the salt stress on and off every minute or every 32 minutes. But to their surprise, when they tried an eight-minute oscillation of precisely the same salt level the cells quickly stopped growing and began to die off.
“That was just a jaw-dropping moment,” said Mitchell. “These cells should be able to handle this level of osmotic stress, but at one particular frequency they just go haywire. We’d never seen anything like this before.”
Could sensory illusions be used to fight cancer?
Mitchell, who was first author on the new study, went on to inspect the cellular mechanism underlying this unexpected, frequency-dependent toxicity. Using mathematical modeling and experiments in which he tweaked the molecular wiring of the mitogen activated protein kinase (MAPK) pathway that mediates the cells’ salt-sensing system, he revealed a sensory misperception: Because of the way the MAPK pathway is set up, the cells interpret an eight-minute oscillation as an ever-increasing staircase of salt concentration. This leads to excessive activation of the cells’ protective response, and ultimately to their death (see Movie).
The Latest on: Cancer Therapeutics
via Google News
The Latest on: Cancer Therapeutics
- FDA grants orphan drug designation to multitargeted T-cell therapy for pancreatic canceron January 22, 2022 at 5:05 am
The FDA granted orphan drug designation to MT-601, an investigational T-cell immunotherapy, for treatment of advanced or metastatic pancreatic adenocarcinoma.MT-601 (Marker Therapeutics) is an ...
- Skin Cancer Therapeutics Market to See Huge Growth by 2028 | Bristol Myers Squibb, Eli Lilly, Rocheon January 21, 2022 at 3:41 pm
The Latest research study released by HTF MI“Skin Cancer Therapeutics Market” with 100+ pages of analysis on business Strategy taken up by key and ...
- Exploring RNAi and nanotechnology for cancer therapeutics: CSIR studyon January 21, 2022 at 9:20 am
The lack of safe and effective delivery methods for RNAi molecules is one of the key challenges against using RNAi-based therapy in biological systems. Dr. Lekha Dinesh Kumar and her group at ...
- Mirati Therapeutics Presents Positive Clinical Data with Investigational Adagrasib in Patients with KRASG12C-Mutated Gastrointestinal Cancerson January 21, 2022 at 7:00 am
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced positive results from a Phase 2 cohort of the KRYSTAL-1 study evaluating adagrasib at the 600mg ...
- Adaptimmune Therapeutics (NASDAQ:ADAP) Lowered to Sell at Zacks Investment Researchon January 21, 2022 at 12:32 am
Adaptimmune Therapeutics (NASDAQ:ADAP) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Wednesday, Zacks.com reports. According to Zacks, ...
- Prostate Cancer Therapeutics Market to Eyewitness Massive Growth by 2029 | Top Companies – GSK, Sanofi, AbbVie, Pfizer, Abbott, Rocheon January 20, 2022 at 9:11 pm
The Global Prostate Cancer Therapeutics Market to reach a market value of USD 18.71 billion by 2029 while growing at a CAGR of 7.70% in the forecast period of 2022 to 2029. Prostate Cancer ...
- Exploring RNAi and Nanotechnology for Cancer Therapeutics: CCMBon January 20, 2022 at 10:54 am
Researchers from the Centre for Cellular and Molecular Biology (CCMB)- CSIR, based in Hyderabad, in collaboration with the Polymer Science and Engineering Division at CSIR-NCL, have developed ...
- Marker Therapeutics Stock Gains On FDA Orphan Drug Tag For Second MultiTAA-Cell Therapy For Pancreatic Canceron January 20, 2022 at 3:38 am
The FDA has granted Orphan Drug Designation to Marker Therapeutics Inc's (NASDAQ: MRKR) MT-601, a multi-tumor-associated antigen (MultiTAA)-specific T cell product for pancreatic cancer. Following ...
- Leap Therapeutics updates Phase 2 data for DKN-01 in GIT canceron January 19, 2022 at 4:35 am
Leap Therapeutics (LPTX) is trading ~8.8% higher in the pre-market after the company announced updated data from the DisTinGuish study where it evaluates its ...
- Pet Cancer Therapeutics Market revenue to cross USD 432 Mn by 2027: Global Market Insights Inc.on January 19, 2022 at 12:35 am
The pet cancer therapeutics market size is anticipated to record a valuation of USD 432 million by 2027, according to the most recent study by Global Market Insights Inc. The rising disposable income, ...
via Bing News